Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Tropism" patented technology

A tropism (from Greek τρόπος, tropos, "a turning") is a biological phenomenon, indicating growth or turning movement of a biological organism, usually a plant, in response to an environmental stimulus. In tropisms, this response is dependent on the direction of the stimulus (as opposed to nastic movements which are non-directional responses). Viruses and other pathogens also affect what is called "host tropism", "tissue tropism", or "cell tropism"; in which case tropism refers to the way in which different viruses/pathogens have evolved to preferentially target specific host species, specific tissue, or specific cell types within those species. Tropisms are usually named for the stimulus involved (for example, a phototropism is a reaction to sunlight) and may be either positive (towards the stimulus) or negative (away from the stimulus).

Tumor vessel targeting AAV therapy for cancer treatment

The present disclosure relates to novel adeno-associated adenovirus (AAV) vectors comprising targeting peptides. More particularly, the present disclosure relates to an adeno-associated serotype 2 virus vector, AAV2, comprising a transgene encoding LIGHT wherein the viral capsid of the AAV2 vector comprises a targeting peptide that alters its tropism to target tumor endothelial cells; and a use of the carrier. The disclosure also relates to the use of said vectors in therapy, in particular in the treatment of cancer.
Owner:ATLE THERAPEUTICS AB

Bipeptide modified bionic nano-vesicle as well as preparation method and application thereof

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Engineered viral capsid polypeptides and uses thereof

The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polypeptides described herein. Described herein are viral vectors comprising a variant sequence of the capsid gene, VP1. In particular, viral vectors with capsid polypeptide mutations that modify tropism of the viral particles relative to particles with wild-type capsid polypeptide are described.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Phagostimulant for improving prevention and control effect of cotton flower thrips and application of phagostimulant

The invention discloses a phagostimulant capable of improving the prevention and control effect of cotton flower thrips and application of the phagostimulant. The phagostimulant is prepared from the following components in parts by weight: 10 to 30 parts of p-methoxycinnamyl aldehyde, 5 to 40 parts of anisaldehyde, 40 to 70 parts of ethyl nicotinate and 10 parts of a cosolvent. The phagostimulant is prepared from the following components in parts by weight: 10 to 30 parts of p-methoxycinnamyl aldehyde, 5 to 40 parts of anisaldehyde, 40 to 70 parts of ethyl nicotinate and 10 parts of cosolvent. By utilizing the tropism of the cotton flower thrips to specific volatile compounds and through the synergistic effect of the three plant source compounds, pests hidden in stamens, petal wrinkles, leaf backs and other hidden parts are attracted to a pesticide application area, the contact area of insect bodies and the pesticide is remarkably increased, and therefore the prevention and control effect is improved. Field tests show that when an optimal formula (the ratio of p-methoxycinnamaldehyde to anisaldehyde to ethyl nicotinate to the cosolvent is 20: 20: 50: 10) is matched with spinetoram for use, the control effect can reach 84.43%-92.22%, the control effect is remarkably improved compared with that of single use of an insecticide, and a good control effect is shown. The method is safe and environment-friendly, reduces the amount and increases the efficiency, and has remarkable economic and ecological benefits.
Owner:INST OF PLANT PROTECTION HEBEI ACAD OF AGRI & FORESTRY SCI

Self-adjuvanting biomimetic lipid nanoparticle, microfluidic assembly method and anti-tumor application thereof

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Method for inducing salt-tropism to construct spatially hierarchical composite particles and application thereof

The application discloses a method for constructing a space-layered composite particle by salt-tropism induction and application thereof, and comprises the following steps: inoculating functional bacteria into an anaerobic ammonia oxidation granular sludge system, so that the functional bacteria and the anaerobic ammonia oxidation granular sludge form a mixed system; the functional bacteria are heterotrophic bacteria with salt-tolerant characteristics Bacillus pumilus NJUST51 strain; the mixed system is operated under anaerobic conditions, and salt is gradually added into influent, so that the salinity is increased to 0.5% to 1.0%; under the action of salt selection pressure, the functional bacteria are enriched on the surface of the granules to form a space-layered structure, so that a composite granule system is constructed. The application realizes stable construction by salt-tropism induction, improves the salt resistance and toxicant resistance stability of the anaerobic ammonia oxidation system, and expands the application range of the system in treatment of high-salinity and organic-toxicity industrial wastewater.
Owner:HANGZHOU NORMAL UNIVERSITY

Adeno-Associated Virus Variant Capsids with Improved Lung Tropism and Uses Thereof

PendingUS20260014275A1VectorsPeptide/protein ingredientsPneumonocyteDisease
The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.
Owner:4D MOLECULAR THERAPEUTICS INC

Recombinant aavs with improved tropism and specificity

The present disclosure provides a modified AAV capsid protein comprising a targeting peptide, optionally further comprising a liver-toggle mutation. The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue. The present disclosure also provides rAAV compositions comprising MTM1 coding sequences and their use to treat subjects suffering from X-linked myotubular myopathy (XLMTM).
Owner:AFFINIA THERAPEUTICS INC

Adeno-associated virus mutant and use thereof

Provided are an adeno-associated virus mutant and the use thereof. The amino acid sequence of the adeno-associated virus capsid protein mutant comprises a sequence shown as any one of SEQ ID Nos. 1-6. Further provided is the use of the adeno-associated virus capsid protein mutant and an expression vector, host cell and recombinant adeno-associated virus thereof in the preparation of a drug delivery tool for preventing and / or treating muscle or cardiac diseases. The provided adeno-associated virus capsid protein mutant has muscle or heart targeting ability, the muscle targeting ability is increased by a maximum of about 496.41 times, the liver and spleen tropism is nearly 100 times lower than that of a control group, and said mutant has good specificity, and exhibits good effect in NHPs.
Owner:GUANGZHOU PACKGENE BIOTECH CO LTD

NADC34-like prrsv-2 vaccine candidate strain and application thereof

PendingUS20260091100A1SsRNA viruses positive-senseViral antigen ingredientsCytopathic effectSerial passage
Disclosed are an rBJ-VVL plasmid, a mutant strain of NADC34-like PRRSV-2 and a preparation method therefor and application thereof. Further disclosed is an NADC34-like PRRSV-2-specific vaccine. In the present disclosure, a modified strain rBJ-VVL with tropism for Marc-145 cells is obtained by precisely mutating an amino acid at positions 91 / 97 / 98 of GP2a; the modified virus constructed in the present disclosure can be propagated in Marc-145 cells, cause cytopathic effects and form plaques when inoculated into Marc-145 cells for serial passage; the resulting Marc-145 cell-passaged viruses have an extremely viral load, and a large number of new progeny viruses can be obtained in a short time; and the Marc-145-adapative modified strain cultured in the present disclosure is used to create a first NADC34-like PRRSV-2-specific vaccine.
Owner:YANGZHOU UNIV

Recombinant AAVS with improved tropism and specificity

PendingUS20260062450A1Virus peptidesMuscular disorderBio distributionTropism
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR, VIII) and / or a peptide segment in variable region I (VR I). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.
Owner:AFFINIA THERAPEUTICS INC

SMALL ACTIVATING RNA (saRNA) CAPABLE OF ACTIVATING CCAAT ENHANCER BINDING PROTEIN ALPHA (CEBPA) GENE, AND DELIVERY SYSTEM AND USE THEREOF

A small activating RNA (saRNA) capable of activating a CCAAT enhancer binding protein alpha (CEBPA) gene, and a delivery system and use thereof are provided, where sense and antisense strands of the saRNA have nucleotide sequences set forth in SEQ ID NO: 1 to SEQ ID NO: 2, respectively. A biomimetic nano-delivery system for targeted delivery of the saRNA is a biomimetic nanoparticle formed by composite nanoparticle coated by a biomembrane of an inflammatory effector cell, where the composite nanoparticle is formed by histone loading with the saRNA capable of activating the CEBPA gene. The biomimetic nanoparticle can inherit antigens and related membrane functions of the inflammatory effector cell and specifically accumulate at the sites of inflammatory lesions, which enables the biomimetic nanoparticle to not only have a longer circulation time in vivo, but also show inflammatory tropism.
Owner:GUANGZHOU MEDICAL UNIV

Recombinant AAV with improved tropism and specificity

PendingCN122029183AImprove treatment indicatorsVirus peptidesGene therapyBio distributionTropism
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in a variable region VIII (VRVIII). The modified AAV capsid protein may form an rAAV having a preferred tropism, specificity, or biological distribution in vivo or in vitro. The rAAVs of the present disclosure can be used in gene therapy targeting specific tissues.
Owner:AFFINIA THERAPEUTICS INC

Porcine reproductive and respiratory syndrome mutant virus and construction method and application thereof

The application discloses a porcine reproductive and respiratory syndrome mutant virus and a construction method and application thereof. The application accurately analyzes key amino acid sites of PRRSV-1 determining Marc-145 cell tropism, specifically, 88(F), 94(I) and 95(L) amino acids of GP2a, 70(G), 72(N), 80(D), 154(I), 158(H) and 163(L) amino acids of GP3, and 49(D), 53(L), 54(R) and 57(G) amino acids of GP4. Three Marc-145 cell non-adapted strains are precisely point mutated, three PRRSV-1 modified strains which can adapt to Marc 145 cell in vitro passage culture are obtained, the strains can be stably passed in vitro and have good replication efficiency, and Marc-145 cells infected by the strains can produce obvious cytopathic effect, and the strains are expected to be used as a new type of PRRSV-1 vaccine.
Owner:YANGZHOU UNIV

Composition containing renal-tropic AAV and method of use thereof

Recombinant adeno-associated virus (AAV) vectors are a major gene delivery platform, and the clinical use of several AAV-mediated therapies has recently been approved. Disclosed herein are compositions comprising AAV capsid proteins exhibiting improved tropism and improved transduction efficiency to renal cells and kidney-associated cells, as well as methods for using AAV particles and AAV vectors containing these AAV capsid proteins to efficiently deliver a gene or transgene of interest to target cells or tissues, and to treat subjects requiring treatment.
Owner:DUKE UNIV

Method for characterizing the electro-taxis of plant roots and its applications

The present application relates to the technical field of plant electric response, in particular to a method for characterizing the electric dual tropism of plant roots and application thereof, two metal plates are inserted into two sides of a cuboid water tank in parallel, the two metal plates are connected with the positive and negative poles of a direct current power supply respectively, a culture medium is added into the water tank to form a closed loop, seeds are placed on a sponge and covered with double-layer gauze, then the sponge is put into the culture medium in the water tank to culture the seeds; the voltage intensity applied to the two sides of the culture medium and the current intensity flowing through the culture medium are adjusted, so that the roots grown from the seeds grow towards the cathode and anode directions, thereby the electric dual tropism of the plant roots is characterized. The method is simple, easy to operate and convenient to observe, can clearly characterize the electric dual tropism of the plant roots, and can reflect the electric response conditions and electric response characteristics when the electric dual tropism occurs, and has a broad application prospect.
Owner:FUJIAN AGRI & FORESTRY UNIV

Generation of adeno-associated virus capsid libraries of insect cells

The present invention relates to means and methods for producing adeno-associated virus capsid libraries using insect host cells. In particular, the present invention relates to novel DNA constructs and methods of using these constructs to produce libraries of adeno-associated virus capsids in insect host cells, which minimize the occurrence of cross-packaging and chimeric phenomena in these libraries produced. The present invention further relates to methods for identifying AAV capsid variants having one or more desired characteristics such as, for example, a combination of CNS tropism and peripheral organ de-targeting.
Owner:UNIQURE BIOPHARMA BV

Equipment for controlling movement behaviors of living insects and design method and application of equipment

The invention relates to equipment for controlling movement behaviors of living insects and a design method and application of the equipment. The invention develops a design method of insect control equipment which is not dependent on electrical stimulation, carries out a biological mechanism experiment and a light source attraction experiment on a target insect, explores the photoelectric physiological effect and phototaxis of the insect, obtains an insect tropism light source, and further designs an electronic backpack for emitting the insect tropism light source, so that the movement control of the insect can be realized; an electrode implantation process is avoided, so that no injury is caused to organisms; the carrying process of the electronic knapsack is fast without professional training; the optical signals hardly have negative effects on insect bodies, and can work for a long time.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Adeno-associated virus variant capsids

The present disclosure generally relates to engineered viral capsid polypeptides with enhanced tropism to certain target tissues and uses thereof. Also disclosed are polynucleotides encoding the engineered viral capsid polypeptides, and vectors, cells, or compositions comprising the same and uses thereof.
Owner:WESTLAKE GENETECH LTD +1

Kit for efficiently capturing fungal pathogen nucleic acid from soil as well as preparation method and application of kit

The invention discloses a kit for efficiently capturing fungal pathogen nucleic acid from soil as well as a preparation method and application of the kit. The preparation method comprises the following steps: the kit comprises a solid culture medium enrichment bar, a rapid lysis solution and a neutralization solution. After the enrichment bar is inserted into the soil to be detected, the pathogenic bacteria are enriched on the culture medium matrix of the enrichment bar by utilizing the isotropic growth of the pathogenic bacteria, and the target pathogenic bacteria are physically purified from the soil environment rich in inhibitors. According to the method, nucleic acid purification is not needed, rapid alkali lysis can be directly carried out on the enriched product, and the obtained nucleic acid lysis solution can be directly used as a detection template for high-sensitivity molecular detection. According to the method, the problem of interference of the soil inhibitor on molecular detection is fundamentally solved, high-difficulty soil nucleic acid extraction is simplified into high-efficiency rapid nucleic acid extraction, and a key solution is provided for field on-site detection.
Owner:JIANGSU OCEAN UNIV

II type herpes simplex virus strain HSV-2 / KM-1 and application thereof

PendingCN122012419AMicroorganism based processesUnknown materialsBALB/cType ii herpes simplex
The invention relates to a type II herpes simplex virus strain HSV-2 / KM-1 and application thereof, and belongs to the technical field of virus microorganisms. The II-type herpes simplex virus strain HSV-2 / KM-1 is preserved in the China Center for Type Culture Collection on July 25, 2025, and the preservation number of the II-type herpes simplex virus strain HSV-2 / KM-1 is CCTCC (China Center for Type Culture Collection) NO: V202550. The II-type herpes simplex virus strain HSV-2 / KM-1 disclosed by the invention has cell tropism and tends to infect genital epithelial cells; the II-type herpes simplex virus strain HSV-2 / KM-1 is applied to neutralizing antibody detection of mouse serum, and the instrumental effect of the II-type herpes simplex virus strain HSV-2 / KM-1 in immunogenicity evaluation of vaccines is disclosed. According to the invention, the II-type herpes simplex virus strain HSV-2 / KM-1 is simultaneously utilized to successfully construct a Hartley guinea pig genital herpes model or a BALB / c mouse genital herpes model, and the models can be used as new tools for HSV-2 vaccine evaluation.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Recombinant AAVS with improved tropism and specificity

PendingCN120897925AVirus peptidesMuscular disorderBio distributionTarget peptide
The present invention provides a modified AAV capsid protein comprising a targeting peptide within variable region VIII (VR VIII) and / or a peptide fragment within variable region I (VR I). The modified AAV capsid proteins may form rAAVs having a specific tropism, specificity, or biodistribution in vivo or in vitro. The rAAV of the invention can be used for gene therapy for specific tissues.
Owner:AFFINIA THERAPEUTICS INC

Engineered AAV capsid polypeptides and methods of use

Described herein are engineered and chimeric VP capsid polypeptides with enhanced tropism for target tissues (e.g., CNS or eye tissues) and enhanced functional transduction. The engineered VP capsid polypeptides are capable of assembling into recombinant AAV (rAAV) capsids for delivery of payload sequences to target tissues (e.g., CNS or eye tissues). Also described herein are methods of using rAAV capsids assembled from the engineered VP capsid polypeptides to deliver and express a payload, such as a guide RNA, in target tissues (e.g., CNS or eye tissues).
Owner:SHAPE THERAPEUTICS INC +11

Recombinant aav with improved tropism and specificity

PendingCN122341627ABio distributionTropism
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII) and / or a peptide segment in variable region I (VR 1). The modified AAV capsid protein can form a rAAV that has a preferred tropism, specificity, or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapy targeted at a particular tissue.
Owner:FEIYA BIOPHARMACEUTICALS